Companies in #Inflammatory Diseases

Formation Bio is an AI-native drug development company building a clinical-stage pipeline through in-licensing and asset acquisition, with a focus on using technology and AI to accelerate clinical trial execution. In early 2026, the company launched a new subsidiary, Kenmare Bio, to develop a miR-124 inhibitor licensed from a Chinese partner for inflammatory diseases.

Biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. Its lead asset LISRAYA (brepocitinib) received FDA approval for dermatomyositis, with Orsini Specialty Pharmacy serving as the specialty pharmacy partner.